(Cost)-effectiveness of self-treatment of exacerbations on the severity of exacerbations in patients with COPD: the COPE II study
- PMID: 19736179
- DOI: 10.1136/thx.2008.112243
(Cost)-effectiveness of self-treatment of exacerbations on the severity of exacerbations in patients with COPD: the COPE II study
Abstract
Background: Chronic obstructive pulmonary disease (COPD) is a chronic disease with a high prevalence and rapidly increasing incidence rates. The effect of self-treatment of COPD exacerbations on the severity of exacerbations during a 1-year period was examined and a cost-effectiveness analysis was performed.
Methods: Patients were randomly allocated to four 2-hour self-management sessions, with or without training in self-treatment of exacerbations. Patients in the self-treatment group received an action plan with the possibility to initiate a course of prednisolone (with or without antibiotics). During follow-up, all participants kept a daily symptom diary. These provided the data to calculate the frequency of exacerbations, the number of exacerbation days and mean daily severity scores.
Results: Data were analysed for 142 randomised patients (self-treatment: n = 70; control: n = 72). The frequency of exacerbations was identical in both study groups (mean (SD) 3.5 (2.7)). Patients in the self-treatment group reported fewer exacerbation days (median 31 (interquartile range (IQR) 8.9-67.5) in the self-treatment group vs 40 (IQR 13.3-88.2) in the control group; p = 0.064); the difference was significant in the group of patients with a high number of exacerbation days per year (>137 (90th percentile of the whole study population); p = 0.028). The mean severity score of an exacerbation day was equal in both groups. No between-group differences were found in health-related quality of life. Cost-effectiveness analyses showed that applying self-treatment saved euro154 per patient, with a trend towards a lower probability for hospital admissions (0.20/patient/year in the self-treatment group vs 0.33/patient/year in the control group; p = 0.388) and a significant reduction of health care contacts (5.37/patient/year in the self-treatment group vs 6.51/patient/year in the control group; p = 0.043).
Conclusion: Self-treatment of exacerbations incorporated in a self-management programme leads to fewer exacerbation days and lower costs.
Comment in
-
Action plans for COPD self-management. Integrated care is more than the sum of its parts.Thorax. 2011 Nov;66(11):935-6. doi: 10.1136/thoraxjnl-2011-200783. Epub 2011 Aug 3. Thorax. 2011. PMID: 21813621 No abstract available.
Similar articles
-
(Cost-)effectiveness of self-treatment of exacerbations in patients with COPD: 2 years follow-up of a RCT.Respirology. 2016 Apr;21(3):497-503. doi: 10.1111/resp.12697. Epub 2015 Dec 9. Respirology. 2016. PMID: 26647766 Clinical Trial.
-
Impact of exacerbations on health care cost and resource utilization in chronic obstructive pulmonary disease patients with chronic bronchitis from a predominantly Medicare population.Int J Chron Obstruct Pulmon Dis. 2012;7:757-64. doi: 10.2147/COPD.S36997. Epub 2012 Nov 1. Int J Chron Obstruct Pulmon Dis. 2012. PMID: 23152680 Free PMC article.
-
Effect of an action plan with ongoing support by a case manager on exacerbation-related outcome in patients with COPD: a multicentre randomised controlled trial.Thorax. 2011 Nov;66(11):977-84. doi: 10.1136/thoraxjnl-2011-200071. Epub 2011 Jul 23. Thorax. 2011. PMID: 21785156 Clinical Trial.
-
Effects of written action plan adherence on COPD exacerbation recovery.Thorax. 2011 Jan;66(1):26-31. doi: 10.1136/thx.2009.127621. Epub 2010 Oct 30. Thorax. 2011. PMID: 21037270 Clinical Trial.
-
Exacerbations of chronic obstructive pulmonary disease.Respir Care. 2003 Dec;48(12):1204-13; discussion 1213-5. Respir Care. 2003. PMID: 14651761 Review.
Cited by
-
Cystic fibrosis telemedicine in the era of COVID-19.JAMIA Open. 2022 Feb 9;5(1):ooac005. doi: 10.1093/jamiaopen/ooac005. eCollection 2022 Apr. JAMIA Open. 2022. PMID: 35224457 Free PMC article.
-
The Importance of Self-Management in the Context of Personalized Care in COPD.Int J Chron Obstruct Pulmon Dis. 2022 Jan 22;17:231-243. doi: 10.2147/COPD.S343108. eCollection 2022. Int J Chron Obstruct Pulmon Dis. 2022. PMID: 35095272 Free PMC article. Review.
-
Self-management interventions for people with chronic obstructive pulmonary disease.Cochrane Database Syst Rev. 2022 Jan 10;1(1):CD002990. doi: 10.1002/14651858.CD002990.pub4. Cochrane Database Syst Rev. 2022. PMID: 35001366 Review.
-
Integrated disease management interventions for patients with chronic obstructive pulmonary disease.Cochrane Database Syst Rev. 2021 Sep 8;9(9):CD009437. doi: 10.1002/14651858.CD009437.pub3. Cochrane Database Syst Rev. 2021. PMID: 34495549 Review.
-
Management and outcomes of patients with chronic obstructive lung disease and lung cancer in a public healthcare system.PLoS One. 2021 May 17;16(5):e0251886. doi: 10.1371/journal.pone.0251886. eCollection 2021. PLoS One. 2021. PMID: 33999942 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical